Form 4: Vaxcyte SVP Mikhail Eydelman Reports Stock Option Exercise and Share Sales
SEC Form 4 Filing
Mikhail Eydelman, SVP, General Counsel & Corporate Secretary of Vaxcyte, Inc., reports exercising stock options and selling shares under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On January 6, 2025, Mikhail Eydelman, SVP, General Counsel & Corporate Secretary of Vaxcyte, Inc., exercised stock options to acquire 5,000 shares of common stock at a price of $21.41 per share.
- Eydelman also sold 954 shares at an average price of $84.856, 3,921 shares at an average price of $85.732, and 125 shares at $86.52.
- These transactions were executed under a Rule 10b5-1 trading plan adopted on June 11, 2024.
- Following these transactions, Eydelman directly owns 28,222 shares of Vaxcyte common stock and holds options for 154,497 shares.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing insider trading activity. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about transactions.
Industry Context
Form 4 filings are standard disclosures required by the SEC when company insiders, like officers and directors, trade their company's stock. These filings provide transparency into insider transactions and are closely watched by investors.
Comparison to Industry Standards
- Insider trading activity is common across publicly listed companies, and Form 4 filings are a standard part of regulatory compliance.
- The use of Rule 10b5-1 trading plans is a common practice to allow insiders to sell shares without being accused of trading on non-public information.
- Comparable companies such as Moderna, BioNTech, and Novavax also have frequent Form 4 filings related to insider transactions.
Stakeholder Impact
- The transactions may have a minor impact on shareholders as they reflect insider selling activity, which can sometimes be interpreted negatively.
- However, the use of a pre-arranged trading plan mitigates concerns about insider information being used for trading purposes.
Key Dates
| Date | Description |
|---|---|
| June 11, 2024 | Date of adoption of Rule 10b5-1 trading plan |
| January 6, 2025 | Date of stock option exercise and share sales |
| January 7, 2025 | Date of signature on the Form 4 filing |
| May 8, 2032 | Expiration date of stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.